Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD – Research Report), with a price target ...

Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Right now, ResMed is sporting a Zacks Rank of #2 (Buy), while Insulet has a Zacks Rank of #3 (Hold). This means that RMD's earnings estimate revision activity has been more impressive, so investors ...